AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02597257
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline continuous infusion
Trial: NCT03410030
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination therapy
Trial: NCT01903057
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01903057
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00624455
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00620919
Drug: RG1068 (Synthetic Human Secretin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Trial: NCT04499209
Drug: Combination of Naproxen and Pregabalin
RxNorm normalized name: naproxen and diphenhydramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
Trial: NCT01437735
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QAW039 po
Trial: NCT01437735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03008005
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
Trial: NCT03358147
Drug: GP MDI 28.8 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
Trial: NCT03358147
Drug: GP MDI 14.4 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
Trial: NCT03358147
Drug: GP MDI 7.2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
Trial: NCT03358147
Drug: Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken as 2 inhalations BID
Trial: NCT03358147
Drug: Spiriva Respimat 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiriva Respimat 2.5 μg QD (open-label)
Trial: NCT01756716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 8 weeks
Trial: NCT02694653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
Trial: NCT02694653
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
Trial: NCT03575351
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care
Trial: NCT00646984
Drug: Standard continuous antiretroviral therapy
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00646984
Drug: CD-4 guided therapy interruption
RxNorm normalized name: Zostrix Cold Therapy 4 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
Trial: NCT00646984
Drug: Viral load driven treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
Trial: NCT04535986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Formulation: Ensifentrine Placebo Nebulizer solution Frequency: Twice Daily for 24 weeks or 48 weeks
Trial: NCT00630253
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
Trial: NCT01328782
Drug: Oxycodone with Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
Trial: NCT03312894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets
Trial: NCT01129479
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill each morning with food for 12 weeks.
Trial: NCT00314093
Drug: RFT5pdgA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02556814
Drug: Caffeic acid tablets
RxNorm normalized name: caffeic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
Trial: NCT02556814
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo tablets 0.3g three times per day for 3 months
Trial: NCT00070122
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00070122
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00070122
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01257451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 50mg bid
Trial: NCT02637180
Drug: anti-osteoporotic medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: check previous information
Trial: NCT00476034
Drug: lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01799850
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo assigned randomly, double blind
Trial: NCT04229394
Drug: 2ccPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1
Trial: NCT04229394
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1
Trial: NCT01046084
Drug: Prevacid®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Delayed-Release Capsule
Trial: NCT00958152
Drug: VCH-222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
Trial: NCT00958152
Drug: VCH-222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
Trial: NCT00958152
Drug: VCH-222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
Trial: NCT04009941
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5mg per cycle, 24 hours after chemotherapy
Trial: NCT03247530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered once daily
Trial: NCT03247530
Drug: 100mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg SPN-812 was administered once daily and compared to placebo
Trial: NCT00929006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Trial: NCT00459407
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT03247530
Drug: 200mg SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Trial: NCT02256930
Drug: M518101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03732833
Drug: MT10109L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109L will be injected into either the LCL, or both the LCL and GL.
Trial: NCT03732833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Trial: NCT02256930
Drug: M518101 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04997551
Drug: Colchcine
RxNorm normalized name: COLCHCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day
Trial: NCT00000534
Drug: calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00694291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT04320745
Drug: Androderm®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androderm® transdermal dose.
Trial: NCT02605642
Drug: CT-P13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biosimilar infliximab
Trial: NCT02601924
Drug: 20% Benzocain (Master-Dent, Monroe, NC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
Trial: NCT00546637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02533427
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet administered orally once daily
Trial: NCT00096460
Drug: Non-myeloablative Conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
Trial: NCT02533427
Drug: Norgestimate/ethinyl estradiol
RxNorm normalized name: Norgestimate/Ethinyl Estradiol 28-Day 0.215mg-0.025mg/0.25mg-0.025mg/0.18mg-0.025mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
Trial: NCT00022139
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01390909
Drug: Anti-epileptic drug (AED)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
Trial: NCT05324891
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
Trial: NCT00855660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as a single tablet, thrice daily, over 14 days.
Trial: NCT01577173
Drug: MEHD7945A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1100 mg iv every 2 weeks
Trial: NCT00568555
Drug: Placebo - sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill once daily
Trial: NCT03792139
Drug: LY3200882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00046839
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00662896
Drug: naproxen 250 mg bid
RxNorm normalized name: naproxen 250 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 250 mg bid
Trial: NCT00662896
Drug: naproxen 500 mg bid
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg bid
Trial: NCT00662896
Drug: ibuprofen 600 mg tid
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 600 mg tid
Trial: NCT01887795
Drug: WBRT
RxNorm normalized name: Whole Brain Radiation Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03548155
Drug: atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any atypical antipsychotic drug as the basic treatment
Trial: NCT03548155
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
Trial: NCT01650155
Drug: BI 1005273 s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT01650155
Drug: BI 105273 i.v. Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT01650155
Drug: BI 1005273 s.c. Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT01650155
Drug: BI 1005273 i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion
Trial: NCT03864458
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03864458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT02582307
Drug: Acetaminophen, Analgesics, Non-Narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose
Trial: NCT02582307
Drug: Hyoscine butylbromide, Analgesics, Non-Narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose
Trial: NCT01006954
Drug: Flare up
RxNorm normalized name: OATMEAL 1 g in 100 g TOPICAL CREAM [Eucerin Eczema Relief Flare Up Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flare up protocol in poor responders for IVF/ICSI
Trial: NCT02011451
Drug: 95% Pure ECGC capsules 200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theaphenon 95% 95% Pure EGCG
Trial: NCT02011451
Drug: Placebo Comparator:
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03350191
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT03350191
Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT01277510
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets and capsules for sprinkling identical to active treatment.
Trial: NCT01277510
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
Trial: NCT01291173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken once daily for up to 11 weeks
Trial: NCT02118792
Drug: AN2728 Topical Ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02118792
Drug: Matching vehicle control
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00485888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to Cipralex
Trial: NCT00653250
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
Trial: NCT01611506
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Trial: NCT02013050
Drug: SGX942
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02013050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03825198
Drug: NaCL 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Trial: NCT03825198
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
Trial: NCT01266954
Drug: GSK2141795
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
Trial: NCT03629067
Drug: Treatment T
RxNorm normalized name: Lice Treatment Topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
Trial: NCT02461563
Drug: 200 mg MK-1075
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Trial: NCT03825198
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
Trial: NCT02461563
Drug: 400 mg MK-1075
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Trial: NCT02835157
Drug: Balanced crystalloid solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple electrolyte solution as boluses would be administered.
Trial: NCT02461563
Drug: 800 mg MK-1075
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
Trial: NCT00003479
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Trial: NCT04123587
Drug: discontinuation of Sulfonylureas
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent
Trial: NCT00748787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
Trial: NCT02597049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00966628
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
Trial: NCT04416854
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
Trial: NCT04416854
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1